MEDIA RELEASE
FOR IMMEDIATE RELEASE

28 November 2017

A STEP FORWARD IN MENDING DAMAGED LUNGS USING STEM CELLS

Researchers demonstrate that lung stem cells can help regenerate injured lungs in laboratory mice

Singapore New research has discovered a means to partially repair damaged lungs. This holds promise for developing strategies to treat lung diseases that are incurable or not easily managed.



times, generating 100 billion billion, or 10^{20} billion, new lung stem cells over the course of six months.

Upon injection into the toxin-injured lungs of laboratory mice, researchers discovered that the lung stem cells could regenerate new airway and alveolar lung tissue. This constitutes one of the first demonstrations that lung stem cells could be used to regenerate lung tissue. Dr Bing Lim, a Senior Group Leader at GIS and Dr Kyle Loh, the Siebel Investigator at Stanford University, share senior authorship of the study.

Despite progress in treating other types of diseases, lung diseases are amongst the most fatal with few known cures. They place a heavy burden on society, said Dr Lim. New

Notes to Editor:
The research findings described in this media release can be found in the scientific journal *Nature Methods,* under the title, *"Isolation and 3D expansion of multipotent Sox9^{+} mouse lung progenitors"* by Massimo Nichane[1], Asif Javed[2], V Sivakamasundari[3], Monisha Ganesan[1], Lay Teng Ang[1], Petra Kraus[4], Thomas Lufkin[4], Kyle M Loh[5,7] & Bing Lim[1,6,7]

[1]Stem Cell & Regenerative Biology Group, Genome Institute of Singapore, A*STAR, Singapore. [2]Cancer Therapeutics & Stratified Oncology Group, Genome Institute of Singapore, A*STAR, Singapore. [3]The Jackson Laboratory for Genomic Medicine, Farmington, Connecticut, USA. [4]Department of Biology, Clarkson University, Potsdam, New York, USA. [5]Stanford Institute for Stem Cell Biology and Regenerative Medicine and the Stanford-UC Berkeley Siebel Stem Cell Institute, Stanford University School of Medicine, Stanford, California, USA. [6]Present address: Translational Medicine Research Centre, Merck Sharp and Dohme, Singapore. [7]These authors jointly directed this work.
Correspondence should be addressed to B.L. (limb1@gis.a-star.edu.sg), K.M.L. (kyleloh@stanford.edu) or M.N. (massimon@gis.a-star.edu.sg).

For media queries and clarifications, please contact:

Winnie Lim
Head, Office of Corporate Communications
Genome Institute of Singapore, A*STAR
Tel: +65 6808 8013
Email: limcp2@gis.a-star.edu.sg

About the Agency for Science, Technology and Research (A*STAR)
The Agency for Science, Technology and Research (A*STAR) is Singapore's lead public sector agency that spearheads economic oriented research to advance scientific discovery and develop innovative technology. Through open innovation, we collaborate with our partners in both the public and private sectors to benefit society.

As a Science and Technology Organisation, A*STAR bridges the gap between academia and industry. Our research creates economic growth and jobs for Singapore, and enhances lives by contributing to societal benefits such as improving outcomes in healthcare, urban living, and sustainability.

We play a key role in nurturing and developing a diversity of talent and leaders in our Agency and Research Institutes, the wider research community and industry. A*STAR